FindTrial
Sign In

Assessment of Medovaha Srotodushti in Type 2 Diabetes Mellitus: A Comparative Study of Patients With and Without Non-Alcoholic Fatty Liver Disease

Development and Validation of Medovaha Srotodushti Nidana Questionnaire and Analytical Cross-Sectional Study to Compare Degree and Pattern of Medovaha Srotodushti in Type 2 Diabetes Mellitus Patients With and Without Non-Alcoholic Fatty Liver Disease (NAFLD) - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/01/100074
Enrollment
140
Registered
2026-01-01
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E889- Metabolic disorder, unspecified Health Condition 2: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

National Institute of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Group1 Patients of either sex aged between 18 to 70 years, Patients diagnosed as Prameha (Type 2 Diabetes Mellitus) with fasting plasma glucose level 126 mg per dl or higher and or HbA1C level more than 6.4 percentage, Individuals with non-alcoholic fatty liver disease Group 2 Patients of either sex aged between 18 to 70 years, Patients diagnosed as Prameha (Type 2 Diabetes Mellitus) with fasting plasma glucose level 126 mg per dl or higher and or HbA1C more than 6.4 percentage.

Exclusion criteria

Exclusion criteria: group 2 Patients diagnosed with Type 1 Diabetes Mellitus (IDDM) Patients with malignancies or any other serious illness. Pregnant and lactating women. Alcohol consumption more than 20 g per day (women) and more than 30 g per day (men). Patients with alcoholic fatty liver disease Group 2 Patients diagnosed with Type 1 Diabetes Mellitus (IDDM). Patients with malignancies or any other serious illness. Pregnant and lactating women. Patients diagnosed with diabetes insipidus Patients with alcoholic and non alcoholic fatty liver disease

Design outcomes

Primary

MeasureTime frame
To Evaluate the effectiveness of the developed tool in evaluating Medovaha Srotodushti in Type 2 Diabetes Mellitus (T2DM) with or without Non-Alcoholic Fatty Liver Disease (NAFLD).Timepoint: At the end of the study—

Secondary

MeasureTime frame
To Evaluate the effectiveness of the developed tool in evaluating Medovaha Srotodushti in Type 2 Diabetes Mellitus (T2DM) with or without Non-Alcoholic Fatty Liver Disease (NAFLD).Timepoint: At the end of the study—

Countries

India

Contacts

Public ContactGanpat Kumar

National Institute of Ayurveda, Jaipur

ssurendra452@gmail.com9414361874

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026